placeholder to show this banner

ashbanner

Arcellx’s anitocabtagene autoleucel (anito-cel) is the first BCMA CAR T to be investigated in multiple myeloma that utilizes our novel and compact D-Domain binder.

Arcellx is pleased to present new clinical data for its iMMagine-1 study in patients with relapsed or refractory multiple myeloma at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando, FL. Presentations may be downloaded below at the specified time. Those attending live can find us at booth #1363 to learn more about our lead clinical asset, anitocabtagene autoleucel (anito-cel).

ASH 2025 Resources

#256: Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine-1
Press Release
Presentation

Management to host an Investor Relations event with a panel of clinician experts to discuss the latest data from the company’s Phase 2 pivotal iMMagine-1 study in patients with RRMM
Presentation

#6344: Visualizing geographic variation and systemic inequities of disease burden and CAR T-cell therapy access in multiple myeloma in the US
Presentation



#256: Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine-1

Presentation Details:
Speaker
Krina K. Patel, MD, MSc, MD Anderson Cancer Center
Session Name
655. Multiple Myeloma: Cellular Therapies: Clinical Trial Advances in CAR T-Cell Therapy for Multiple Myeloma
Session Date
Saturday, December 6, 2025
Session Time
2:00 p.m. – 3:30 p.m. ET
Presentation Time
2:45 p.m. ET
Location
OCCC – West Hall E1
Publication Number
256
Submission ID
abs25-4541

#6344: Visualizing geographic variation and systemic inequities of disease burden and CAR T-cell therapy access in multiple myeloma in the US

Presentation Details:
Speaker
Brandon Blue, MD, Moffitt Cancer Center
Session Name
907. Outcomes Research: Plasma Cell Disorders: Poster III
Session Date
Monday, December 8, 2025
Session Time
6:00 p.m. – 8:00 p.m. ET
Location
OCCC – West Halls B3-B4
Publication Number
6344
Submission ID
abs25-2093

Press Releases
Presentations